Advertisement

Neurological Sciences

, Volume 31, Supplement 1, pp 175–177 | Cite as

The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline

  • Fabio Valguarnera
  • Paolo Tanganelli
Oral Communication

Abstract

Management of patients affected by chronic daily headache (CDH) with medication overuse constitutes one of the most important unresolved problems. The uncertainty regarding the classification and the prophylaxis are a remarkable part of this problem. Objectives are to: (1) to evaluate the efficacy of withdrawal therapy following prophylaxis with topiramate and amitriptyline in a population affected by CDH and medication overuse with follow-up at 1 (T1), 3 (T2) and 6 (T3) months; (2) to identify which group of the Silberstein’s CDH classification (1994) may benefit from this protocol. Inclusion criteria are patients with CDH (headache for more >15 days/month for at least 3 consecutive months) and medication overuse according with IHS second edition (8.2 group); exclusion criteria are patients with secondary headache. All patients included in the study were hospitalized for 1 week. Type of overuse: combination of medications, 38%; analgesics, 29%; triptans, 29%; opioids, 2%; ergotamines, 2%. During hospitalization the following protocol was applied: desametasone 4 mg i.v./day for 1 week, diazepam 6 mg/day for 10 days and prophylaxis with amitriptylin plus topiramate. This prophylaxis was protracted for at least 6 months. The dosages assumed ranged for amitriptylin from 10 to 20 mg/day and for topiramate from 50 to 100 mg/day. In the last 4 years 105 patients with CDH (age 24–89 years; f 96; m 9) were admitted to the hospital. The protocol was applied in 52 patients (age, 29–65 years; f 49; m 3). At T1, 89% of the patients did not fall again into medication overuse; at T2, 64%; and at T3,45% of the patients remained free from overuse. According to the Silberstein’ proposal at T1, 93% of the subjects was affected by transformed migraine; and 7% by tension-type headache. At T3, all the patients free from overuse were affected by transformed migraine. Our data suggest that the patients affected by CDH and medication overuse benefit from withdrawal therapy performed during hospitalization plus prophylaxis with amitriptyline plus topiramate. This combination seems a good pharmacological solution to reduce the risk of relapse.

Keywords

Chronic daily headache Medication overuse Withdrawal therapy Topiramate/amitriptyline 

Notes

Conflict of interest statement

The authors declare that they have no conflict of interest related to the publication of this article.

References

  1. 1.
    Diener HC, Limmroth V (2004) Medication overuse headache: a worldwide problem. Lancet Neurol 3:475–483PubMedCrossRefGoogle Scholar
  2. 2.
    Castillo J, Munoz P, Guitera V, Pascual J (1999) Epidemiology of chronic daily headache in the general population. Headache 39:190–196PubMedCrossRefGoogle Scholar
  3. 3.
    Manack A, Turkel C, Silberstein S (2009) The evolution of chronic migraine: classification a nomenclature. Headache 49:1206–1213PubMedCrossRefGoogle Scholar
  4. 4.
    Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders: 2nd edition. Cephalalgia 24(Suppl 1):9–160Google Scholar
  5. 5.
    Saper JR, Hamel RL, Lake AE III (2005) Medication overuse headache (MOH) is a behavioural disorder. Cephalalgia 25:545–546PubMedCrossRefGoogle Scholar
  6. 6.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD (2005) Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45:315–324PubMedCrossRefGoogle Scholar
  7. 7.
    Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized double-blind, placebo-controlled trial. Headache 45:293–307PubMedCrossRefGoogle Scholar
  8. 8.
    Grazzi L, Andrasik F (2006) Medication overuse headache: description, treatment and relapse prevention. Curr Pain Headache Rep 10:71–77PubMedCrossRefGoogle Scholar
  9. 9.
    Silberstein SD, Lipton RB, Solomon S, Mathew NT (1994) Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 34:1–7CrossRefGoogle Scholar
  10. 10.
    Dierer HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814–823CrossRefGoogle Scholar
  11. 11.
    Mathew NT, Kailasam J, Meadors L (2002) Prophylaxis of migraine, transformed migraine and cluster headache with topiramate. Headache 42:796–803PubMedCrossRefGoogle Scholar
  12. 12.
    Ziegler DK, Hurwitz A, Hassaneim RS, Kodanaz HA, Preskom SH, Mason J (1987) Migraine prophylaxis: a comparison of propranolol and amitriptyline. Arch Neurol 44:486–489PubMedGoogle Scholar
  13. 13.
    Mathew NT (1981) Prophylaxis of migraine and mixed headache: a randomized controlled study. Headache 21:105–109PubMedCrossRefGoogle Scholar
  14. 14.
    Couch JR, Hassaneim RS (1979) Amitriptyline in migraine prophylaxis. Arch Neurol 36:695–699PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department Head-Neck, ASL 3 GenoveseP.A. Micone HospitalGenoaItaly

Personalised recommendations